NCT02240706View on ClinicalTrials.gov

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions
Myelodysplastic Syndromes
Interventions
PROCEDURE

Best Supportive Care

At Discretion of the Investigator (Transfusions)

DRUG

BI 836858

Monotherapy with BI 836858

Trial Locations (5)

32224

Mayo Clinic Cancer Center, Jacksonville

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

40225

Universitätsklinikum Düsseldorf, Düsseldorf

44195

Cleveland Clinic, Cleveland

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02240706 - Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter